Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights
July 12 2018 - 2:30PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology
company developing a proprietary therapeutic tissue treatment based
on its Nano-Pulse Stimulation (NPS) platform, today announced that
the Company will report second quarter 2018 operational highlights
and financial results on Tuesday, July 31, 2018. Pulse Biosciences
management will host a conference call and webcast at 4:30 p.m.
Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 3295809. The webcast of
the conference call can be accessed live on the Investor Relations
section of the Pulse Biosciences website at
www.pulsebiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a publicly listed clinical stage
electroceutical company pursuing multiple clinical applications of
its proprietary Nano-Pulse Stimulation technology. Nano-Pulse
Stimulation (NPS) is a non-thermal, precise, focal tissue treatment
technology comprised of nanosecond (billionth of a second) range
pulsed electric fields that directly affect the cell membrane and
intracellular structures and initiates cell death in treated cells.
The initiation of cell death by NPS results in a minimal
inflammatory response, which improves healing outcomes and supports
the replacement of treated tissue cells with healthy tissue cells.
NPS’ unique mechanism of action to initiate cell death has the
potential to significantly benefit patients for multiple medical
applications in dermatology, immune-oncology, and in other unique
tissue targets. In cancerous lesions, NPS has been shown in
preclinical models to induce immunogenic cell death (ICD), which
exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells
to mount an adaptive immune response. More information is available
at www.pulsebiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180712005772/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@pulsebiosciences.comorSolebury TroutGitanjali Jain Ogawa,
646-378-2949gogawa@troutgroup.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024